Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zentalis (Nasdaq: ZNTL) announced an inducement equity grant on May 1, 2026. The Compensation Committee awarded non-qualified stock options for 26,000 shares to one newly hired employee under the 2022 Inducement Plan, with an exercise price of $4.09 per share.

The options carry a 10-year term and vest over four years: 25% at the first anniversary and the remaining 75% in equal monthly installments over the following three years, subject to continued service.

News Market Reaction – ZNTL

-2.20%

-2.20% Session close to close

In the May 4 session, ZNTL declined 2.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard inducement grant of 26,000 non-qualified stock options at $4.09...

Analysis

This announcement details a standard inducement grant of 26,000 non-qualified stock options at $4.09 under Nasdaq Listing Rule 5635(c)(4), with a four‑year vesting schedule and 10‑year term. It follows a similar grant disclosed on April 1, 2026, and sits against a backdrop of more material clinical and financial updates around azenosertib. Investors may watch upcoming DENALI and ASPENOVA milestones for more substantive catalysts.

Key Figures

Inducement options granted: 26,000 shares Newly hired employee: 1 employee Exercise price: $4.09 per share +4 more

7 metrics

Inducement options granted 26,000 shares Non-qualified stock options to one newly hired employee

Newly hired employee 1 employee Recipient of inducement stock option grant

Exercise price $4.09 per share Equal to ZNTL closing price on Nasdaq at grant date

Option term 10 years Contractual life of inducement stock options

Vesting period 4 years Inducement stock options vesting schedule length

Initial vesting tranche 25% Vests on first anniversary of vesting commencement date

Remaining vesting 75% over 3 years Equal monthly installments after first anniversary

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	ASCO abstract acceptance	Positive	-1.0%	ASCO 2026 abstract acceptance highlighting combinability and activity in PROC.
Apr 17	AACR data update	Positive	-7.6%	AACR 2026 preclinical TNBC data and real‑world Cyclin E1 ovarian cancer analysis.
Apr 09	Pivotal dose selection	Positive	+60.1%	Selection of 400mg QD 5:2 azenosertib monotherapy dose for pivotal DENALI study.
Apr 01	Inducement grants	Neutral	+2.3%	Stock options for 36,000 shares granted to two new employees under inducement plan.
Mar 26	Full-year results	Positive	-5.2%	Full-year 2025 results, cash of $245.9M and milestones toward DENALI and ASPENOVA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinically focused news around azenosertib often led to sharp, sometimes divergent moves, with one major rally on pivotal dose selection but several selloffs after otherwise positive updates.

Recent Company History

Over the last few months, ZNTL has issued multiple updates centered on its WEE1 inhibitor azenosertib. On Mar 26, full-year 2025 results and cash runway to late 2027 preceded a -5.24% move. Dose selection for DENALI on Apr 9 coincided with a sharp +60.14% reaction. Subsequent AACR and ASCO-related data updates on Apr 17 and Apr 21 saw shares slip -7.57% and -0.99%. A prior inducement grant on Apr 1 drew a modest +2.33% gain, suggesting routine HR items have had limited impact versus major clinical catalysts.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 26,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on May 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $4.09 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact: 
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

What did Zentalis (ZNTL) grant on May 1, 2026 under Nasdaq Rule 5635(c)(4)?

Zentalis granted non-qualified stock options to purchase 26,000 shares to one newly hired employee. According to the company, the award was an inducement grant under the 2022 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term for the ZNTL inducement stock options?

The options have an exercise price of $4.09 per share and a 10-year term. According to the company, $4.09 equals the Nasdaq closing price on the grant date, May 1, 2026.

How do the Zentalis (ZNTL) inducement options vest over time?

Vesting is over four years: 25% vests at the first anniversary and 75% vests in equal monthly installments over the next three years. According to the company, vesting is subject to the employee's continued service on each vesting date.

Under which plan were the ZNTL inducement options granted and who is eligible?

The grant was made under the 2022 Inducement Plan, used only for hires or rehires as an employment inducement. According to the company, the plan applies exclusively to individuals not previously employed or following a bona fide non-employment period.

Will the Zentalis (ZNTL) inducement grant dilute current shareholders materially?

The company granted 26,000 shares in options to one employee; no percentage dilution figure was provided. According to the company, the award was an individual inducement grant under the 2022 Inducement Plan.